Home

>>

Industry

>>

Bio tech

>>

PDS Biotech's cancer vaccine p...

BIO TECH

PDS Biotech's cancer vaccine performs effectively in a Phase II experiment

cancer vaccine

PDS Biotech's Keytruda, an immune checkpoint inhibitor, has become a blockbuster oncology medicine

PDS Biotechnology announced that PDS0101, its cancer vaccine candidate, met the efficacy threshold in the second stage of a Phase II trial in head and neck cancer. PDS Biotech confirmed that PDS0101 met the objective response criterion as determined by investigators in stage two of the Phase II VERSATILE-002 study (NCT04260126). PDS0101 is being studied in combination with Merck's anti-PD-1 medication Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV 16-positive head and neck cancer.

PDS0101 is a liposomal-based therapeutic vaccination designed to help the immune system respond to tumor cells infected with HPV-16. It is administered subcutaneously either alone or in combination with other immunotherapies and cancer treatments. Keytruda, an immune checkpoint inhibitor, has become a blockbuster oncology medicine with the US Food and medicine Administration (FDA) recently approving its 34th approval.

When 14 of 54 patients in the immune checkpoint inhibitor (ICI) naive arm showed either a complete or partial response on two consecutive scans, PDS0101 passed the effectiveness criteria, confirming an objective response. Additional individuals are still being evaluated for imaging, and the business says it will continue to monitor efficacy and safety.

Client-Speak Magazine Subscribe Newsletter Video
🚀 NOMINATE YOUR COMPANY NOW 🎉 GET 10% OFF 🏆 LIMITED TIME OFFER Nominate Now →